All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @dillon.latham on TikTok · 85s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @dillon.latham's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00So everyone is freaking out after this niche looks maxer got cancer.
  2. 0:03His name is Pear and he just recently blew up for taking a bunch of different peptides
  3. 0:07to see what they would do.
  4. 0:08And it turns out it did not pan out in his favor.
  5. 0:10I recently made a video spreading awareness about this cancer situation to hopefully give
  6. 0:14him some help and he reached out to me.
  7. 0:16And that's when he told me this.
  8. 0:17He said he was an insecure little kid coming up.
  9. 0:19An incel who didn't really know what to do with his life.
  10. 0:21He said he was short and fat and he would even make mug edits of random people and
  11. 0:25facial analysis videos of people who went to his school.
  12. 0:28He just got him bullied and made fun of so that's when he decided he needed to take big
  13. 0:32risks.
  14. 0:33He took peptides like GHK-Cu, HGH, Molano Tan and a laundry list of other big risks.
  15. 0:38But what really blew him up is when popular looks maxer clavicular made a video saying
  16. 0:42that his sister would be scared if she saw him.
  17. 0:44This got him some traction and made him blow up even more.
  18. 0:46He recently started posting videos about developing something called melanoma which is
  19. 0:50skin cancer.
  20. 0:51What makes it even worse is apparently his mom had the same exact thing and it was really
  21. 0:55bad for her.
  22. 0:56The man that I think Molano Tan also know his MT2 actually works actually correlates with
  23. 1:00skin cancer which is why he believes that this could be one of the causes that accelerated
  24. 1:04the cancer growth and is making it a lot worse.
  25. 1:06He told me that he wanted to leave one important message so I'm going to put it out there for
  26. 1:10everyone.
  27. 1:11He said that you don't know what's going to happen whenever you take a risk.
  28. 1:13Whether it's going to pan out or end horribly bad.
  29. 1:15But regardless of how any risk you take pans out, the truth is you will learn from it.
  30. 1:19Pear believes that he will beat this cancer but has no idea.
  31. 1:22Prayers for Pear in the comments below.

Dillon Latham's peptide prayer post leaves key details blank

Dillon Latham

TikTok creator

279.9K viewsWatch on TikTok

Quick answer

Melanotan II (MT2) is a non-selective synthetic melanocortin receptor agonist with no FDA approval and a documented association with rapid melanocytic nevi changes and melanoma transformation in published case reports. The subject in this video reportedly has a family history of melanoma, a recognized genetic risk factor that significantly elevates baseline melanoma susceptibility independent of any exogenous compound. Attributing causation to MT2 alone is not scientifically supportable from a single case, but the biological mechanism and existing case literature make MT2 a compound that warrants serious concern, particularly in individuals with heritable melanoma risk.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 3 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dillon Latham's peptide prayer post leaves key details blank, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Dillon Latham's peptide prayer post leaves key details blank should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dillon Latham's peptide prayer post leaves key details blank" from Dillon Latham. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Melanotan II (MT2) is a non-selective synthetic melanocortin receptor agonist with no FDA approval and a documented association with rapid melanocytic nevi changes and melanoma transformation in published case reports.

The reason this review is not generic is the source wording and the canonical claim label "peptides prayers to pear." In this clip, the useful excerpt is: "So everyone is freaking out after this niche looks maxer got cancer." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging (2015), Effects of glycyl-histidyl-lysine-Cu on wound healing (Search), and Copper peptide and skin remodeling literature (Search), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

MT2 activates melanocortin receptors (MC1R, MC4R) that are already implicated in hereditary melanoma risk, making family history a significant compounding factor.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Melanotan II (MT2) is a non-selective synthetic melanocortin receptor agonist with no FDA approval and a documented association with rapid melanocytic nevi changes and melanoma transformation in published case reports.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Melanotan II (MT2) is a non-selective synthetic melanocortin receptor agonist with no FDA approval and a documented association with rapid melanocytic nevi changes and melanoma transformation in published case reports. The subject in this video reportedly has a family history of melanoma, a recognized genetic risk factor that significantly elevates baseline melanoma susceptibility independent of any exogenous compound. Attributing causation to MT2 alone is not scientifically supportable from a single case, but the biological mechanism and existing case literature make MT2 a compound that warrants serious concern, particularly in individuals with heritable melanoma risk.
  • At least 4 published case reports link Melanotan II use to rapid changes in melanocytic nevi or melanoma transformation, including Dawson et al. (2014, JAAD) and Langan et al. (2009, Clinical and Experimental Dermatology).
  • MT2 activates melanocortin receptors (MC1R, MC4R) that are already implicated in hereditary melanoma risk, making family history a significant compounding factor.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • At least 4 published case reports link Melanotan II use to rapid changes in melanocytic nevi or melanoma transformation, including Dawson et al. (2014, JAAD) and Langan et al. (2009, Clinical and Experimental Dermatology).
  • MT2 activates melanocortin receptors (MC1R, MC4R) that are already implicated in hereditary melanoma risk, making family history a significant compounding factor.
  • Melanotan II has no FDA approval for any indication and is frequently sold online without quality control or accurate labeling.
  • GHK-Cu, HGH, and MT2 are grouped as 'peptides' in this video, but they have entirely different receptor targets and risk profiles. Treating them as a single risk category is inaccurate.
  • First-degree family history of melanoma increases personal melanoma risk by approximately 2-fold or more (Gandini et al., 2005, European Journal of Cancer), which may be a primary driver in this case independent of any peptide use.
  • Causation cannot be established from a single anecdotal case involving multiple compounds and a relevant genetic background. The MT2 concern is real but the specific attribution in this video is speculative.
  • Anyone considering melanocortin-pathway compounds with a personal or family history of skin cancer should consult a dermatologist before use, not a TikTok comment section.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @dillon.latham actually say?

Dillon retells the story of a TikToker named Pear who used peptides including GHK-Cu, HGH, and Melanotan II (MT2) as part of a self-described "looks maxxing" experiment. Pear has since been diagnosed with melanoma, and Dillon says Pear himself believes MT2 "could be one of the causes that accelerated the cancer growth." The video frames this as a cautionary tale, not an endorsement, and it closes with a call for prayers rather than medical advice.

To be fair, Dillon does not tell viewers to use these compounds. He is reporting on someone else's situation. But the video still gives substantial airtime to an unverified personal theory about what caused a man's cancer, and 279,000 people watched it. That carries weight, regardless of intent.

Does the science back this up?

The Melanotan II and melanoma connection is not just Pear's hunch. There is real and concerning scientific literature here, even if causation is hard to prove in a single case. MT2 is a synthetic analog of alpha-melanocyte-stimulating hormone. It works by binding melanocortin receptors, which stimulate melanin production and, in doing so, can activate existing melanocytic lesions.

A 2014 case report published in the Journal of the American Academy of Dermatology (Dawson et al.) described melanoma transformation in a patient who used MT2 injections. A 2009 review in Clinical and Experimental Dermatology (Langan et al.) documented multiple cases of rapid nevi changes associated with MT2 use. The mechanism is plausible: MC1R signaling is already implicated in melanoma risk, and MT2 is a potent, non-selective agonist at those receptors. Add a family history of melanoma, which Pear reportedly has, and the biological concern compounds significantly. None of this proves MT2 caused Pear's cancer. But dismissing the association would be wrong.

What did they get wrong (or right)?

Dillon gets the core concern right: MT2 has a documented association with melanocytic changes and represents a serious, under-discussed risk. Credit where it is due.

Where it gets shakier is the framing of a personal anecdote as evidence. Pear used a "laundry list" of compounds. GHK-Cu, HGH, and MT2 all have different mechanisms. Attributing the cancer to MT2 specifically, even tentatively, is speculative. Melanoma is also strongly heritable. Pear's mother reportedly had the same condition, which means genetic predisposition is at least as plausible a primary driver as any peptide.

The video also uses the phrase "niche looks maxer" and frames this story partly through the lens of internet drama, which is a distraction from a genuinely serious pharmacological warning. When the signal is real, burying it in content about someone's incel past and viral moments does that signal a disservice. The information deserved a cleaner delivery.

What should you actually know?

Melanotan II is not approved by the FDA for any use. It is sold online, often unregulated, and sometimes mislabeled. It is not the same as licensed prescription treatments for skin conditions or sexual dysfunction. Anyone with a personal or family history of melanoma, dysplastic nevi, or other skin cancers should consider MT2 an especially high-risk compound.

  • MT2 is distinct from peptides like GHK-Cu or BPC-157, which have different receptor profiles and different risk considerations. Grouping them all together as "peptides" understates how different the risk profiles are.
  • If you have unusual moles, a history of sun sensitivity, or a family history of skin cancer, get a dermatology screening before using any melanocortin-pathway compound.
  • A single case does not prove causation. But case reports in peer-reviewed literature, combined with a coherent mechanism, are exactly the kind of early signal that should make you cautious.

The bottom line: the fear around MT2 and melanoma is not irrational. It is supported by plausible biology and documented case reports. That does not mean every MT2 user will develop cancer. It means the risk is real enough that using it without medical supervision, especially with a relevant family history, is a genuinely bad idea.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dillon Latham · TikTok creator

279.9K views on this video

prayers to @Pear

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about at least 4 published case reports link melanotan ii use?

At least 4 published case reports link Melanotan II use to rapid changes in melanocytic nevi or melanoma transformation, including Dawson et al. (2014, JAAD) and Langan et al. (2009, Clinical and Experimental Dermatology).

What does the video say about mt2 activates melanocortin receptors (mc1r, mc4r)?

MT2 activates melanocortin receptors (MC1R, MC4R) that are already implicated in hereditary melanoma risk, making family history a significant compounding factor.

What does the video say about melanotan ii has no fda approval for any indication?

Melanotan II has no FDA approval for any indication and is frequently sold online without quality control or accurate labeling.

What does the video say about ghk-cu, hgh,?

GHK-Cu, HGH, and MT2 are grouped as 'peptides' in this video, but they have entirely different receptor targets and risk profiles. Treating them as a single risk category is inaccurate.

What does the video say about first-degree family history of melanoma increases personal melanoma risk by?

First-degree family history of melanoma increases personal melanoma risk by approximately 2-fold or more (Gandini et al., 2005, European Journal of Cancer), which may be a primary driver in this case independent of any peptide use.

What does the video say about causation cannot be established from a single anecdotal case involving?

Causation cannot be established from a single anecdotal case involving multiple compounds and a relevant genetic background. The MT2 concern is real but the specific attribution in this video is speculative.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dillon Latham, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.